go-v.orgdoi

Dual GIP/GLP-1 Receptor Agonists and Kidney Protection: Expanding Therapeutic Horizons in Nephrology

Richard Adrián Vergara Trujillo, Erick Adolfo Meza Soto, José Enrique González Araujo, José Uriel Cornejo Quezada, Luz Elena Prieto Garcerant, Cynthia Michelle Escobar Arévalo, Melany Noelia Hernández Andino, Andrea Carolina Reina Ibarra · IECCMEXICO · 2025

  • DOI 10.64784/007
  • Publisher OpenAlex
  • Type article
  • Issued 2025

Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.

IECCMEXICO · OpenAlex · article · 2025

Abstract

Dual GIP/GLP-1 receptor agonists have emerged as an innovative therapeutic class that combines metabolic and renal protection in patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD). This multicenter study, conducted in Mexico, Colombia, and Ecuador, evaluated the renal and metabolic effects of dual incretin therapy compared with GLP-1 receptor agonists and standard therapy (SGLT2 inhibitors plus RAAS blockade). A total of 1,150 adults with T2DM and CKD stages 1–4 were included.

The dual GIP/GLP-1 group achieved the greatest improvement in kidney outcomes, with a 29% reduction in urinary albumin-to-creatinine ratio (UACR) and the smallest annual decline in estimated glomerular filtration rate (eGFR, −1.6 mL/min/1.73 m²), compared to GLP-1 monotherapy (−2.6) and standard therapy (−3.5). Additionally, participants receiving dual agonists showed superior metabolic control, including reductions in HbA1c (−17.9%), body mass index (−10.6%), and systolic blood pressure (−9.1 mmHg). Overall, 58.9% achieved composite kidney improvement and 76.3% avoided progression to a higher KDIGO risk category.

These results align with international evidence from the SURPASS and FLOW trials, confirming that dual receptor activation offers synergistic mechanisms—anti-inflammatory, antifibrotic, and hemodynamic—that extend renal protection beyond glycemic control. The findings support incorporating dual GIP/GLP-1 receptor agonists into nephrology practice as a next-generation therapy capable of modifying the natural history of diabetic kidney disease and improving long-term clinical outcomes in diverse Latin American populations.

Open the resolved locator · 10.64784/007

Metadata licence: OpenAlex metadata (CC0)